Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
With
National Cancer Institute (NCI)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have a metastatic melanoma diagnosis (stage IV) for which treatment with nivolumab or pembrolizumab, either alone or in combination with other therapies, is planned. No additional laboratory testing is needed for the imaging in this study apart from the standard laboratory testing routinely obtained for treatment with nivolumab or pembrolizumab, either alone or in combination with other therapies.
Participants must have at least 2 subcutaneous or lymph node melanoma metastases that are 2 cm in greatest diameter and are amenable to being biopsied in clinic without requiring image-guidance.
Participants must be able to provide informed consent
Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
You may not be if
Not able to receive treatment with either nivolumab or pembrolizumab.
Women of child-bearing potential must have a negative serum or urine pregnancy test within 7 days of the first study FLT PET/CT and must not be breast feeding for the duration of study participation.
